Treatment Access Solution

A collaboration with Novartis

Glivec® (imatinib)

The Max Foundation’s long-standing shared-value partnership with Novartis was first established in 2002 through the Glivec®International Patient Assistance Program, commonly known by its acronym GIPAP. GIPAP is operating in specific low and middle income countries providing access to Glivec® (imatinib) for people properly diagnosed with chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and orphan indications for which Glivec has been approved. Eligible patients, must meet medical and socio-economic criteria.

Throughout 2017, The Max Foundation and Novartis will be transitioning their partnership around access to Glivec® (imatinib) treatment from the GIPAP model to a new collaboration known as CMLPath to Care™.

CMLPath to Care is a unique global initiative that connects people living with chronic myeloid leukemia (CML) and their carers with effective treatments, professional medical capabilities, trained physicians and hands-on support. The initiative is directed by The Max Foundation with support from Novartis Oncology through drug donations and funding. CMLPath to Care is an evolved compact reflecting a new healthcare environment and the founders’ one simple goal – to enable people living with CML to be well.

View our global map and click on individual countries to learn where these initiatives are operating today. Contact us for more information about access to Glivec® (imatinib) in these countries.

Return to Treatment Access Solutions